- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05458115
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
July 10, 2022 updated by: Anhui Provincial Hospital
ctDNA-based liquid biopsy can better detect the presence of MRD before imaging and serological markers, and is suitable for postoperative MRD and recurrence monitoring, which has been clinically validated in several cancer types such as lung cancer and intestinal cancer.
However, there is no systematic comparative study of postoperative MRD and recurrence monitoring based on ctDNA testing in hepatocellular carcinoma.
A prospective multicenter observational clinical study is proposed to evaluate the use of liquid biopsy based on ctDNA NGS assay in surgical evaluation, MRD and molecular recurrence state monitoring after radical resection of hepatocellular carcinoma, and to compare with imaging and serological findings with the aim of early detection of disease recurrence or metastasis and more survival benefits for patients.
Study Overview
Study Type
Observational
Enrollment (Anticipated)
200
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
HCC patients
Description
Inclusion Criteria:
Inclusion criteria.
- understood and agreed to follow the study requirements, were willing to provide samples for testing, and signed an informed consent form.
- age 18-75 years, regardless of gender.
- patients with a clinical diagnosis of surgically resectable CNLC Ia-IIa hepatocellular carcinoma.
- patients who have not received any previous treatment for their primary treatment and who agree to receive treatment
- an ECOG physical status of 0 or 1 within 1 week prior to enrollment.
- have at least one measurable lesion according to RECIST v1.1 or mRECIST criteria and have not received radiation therapy
- an expected survival time of ≥ 3 months.
- adequate organ function, with the following laboratory test values required within 7 days prior to treatment: - Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, hemoglobin ≥ 90 g/L, and white blood cell count ≥ 3 × 109/L.
Note: Patients should not have received blood transfusion or growth factor support within 14 days prior to blood sample collection.
- International normalized ratio (INR) ≤ 1.5 times the upper limit of normal (1.5 x ULN).
- Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN.
- Total serum bilirubin ≤ 1.5 x ULN (patients with Gilbert syndrome may be enrolled if total bilirubin < 3 x ULN).
- Glutathione aminotransferase (AST) and glutathione alanine aminotransferase (ALT) ≤ 2.5 x ULN.
- Renal function: serum creatinine ≤ 1.5× ULN or creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula
Exclusion Criteria:
- patients with comorbid other active malignancies.
- active infection or known human immunodeficiency virus infection (HIV-positive).
- previous allogeneic stem cell transplantation.
- the patient's compliance during the study period is, in the judgment of the investigator, inadequate
- having received any systemic antineoplastic therapy prior to initiation of study treatment with approved
- has received blood transfusion, radiotherapy, or drug therapy within 1 month prior to enrollment.
- untreated active hepatitis C (patients with positive anti-HCV antibodies or positive HCV RNA cannot be enrolled); untreated active hepatitis B (HBsAg positive and HBV DNA ≥ 2000 IU/mL).
- patients with hepatocellular carcinoma in whom distant metastases, vascular invasion and cancer emboli have been observed on imaging
- women of childbearing age with positive blood pregnancy tests
- subjects with a history of serious systemic disease such as diabetes, hypertension, myocardial infarction, etc., or other reasons believed to interfere with the accuracy of the test, or a combination of serious mental illness, in the opinion of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
liver resection group
|
Patient underwent hepatic R0 resection within a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clinicopathological information recording
Time Frame: 2 years
|
Age, gender, ECOG PS, Child-pugh, tumor stage, cirrhosis, history of hepatitis
|
2 years
|
Adverse effect
Time Frame: 2 years
|
Incidence of adverse reactions after various treatments
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 30, 2022
Primary Completion (ANTICIPATED)
December 31, 2023
Study Completion (ANTICIPATED)
December 31, 2024
Study Registration Dates
First Submitted
September 16, 2021
First Submitted That Met QC Criteria
July 10, 2022
First Posted (ACTUAL)
July 14, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 14, 2022
Last Update Submitted That Met QC Criteria
July 10, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- kyMRD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on Liver resection
-
Fundación de Investigación Biomédica - Hospital...Marcello Di MartinoCompletedMetastatic Colorectal Cancer | Metastatic Liver CancerSpain, United Kingdom, France
-
hui houNot yet recruitingLaparoscopic Liver Resection | Open Liver ResectionChina
-
Fondazione Poliambulanza Istituto OspedalieroThe Queen Elizabeth Hospital; Clinica Universidad de Navarra, Pamplona, Spain; Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands and other collaboratorsCompletedObesity | Liver Metastases | Liver CancerItaly
-
University of MilanUnknownOverall Survival | Patients Affected by Hepatocellular Carcinoma | Disease-Free SurvivalItaly
-
Fudan UniversityNot yet recruitingLiver Metastases | Colorectal CarcinomaChina
-
Oslo University HospitalHelse Sor-OstActive, not recruitingColorectal Neoplasms | Secondary Malignant Neoplasm of LiverNorway
-
Huazhong University of Science and TechnologyNot yet recruitingHepatocellular Carcinoma by BCLC StageChina
-
Fondazione Poliambulanza Istituto OspedalieroIRCCS Azienda Ospedaliero-Universitaria di Bologna; Universita di Verona; University... and other collaboratorsCompletedColorectal Cancer Metastatic | Surgical Procedure, UnspecifiedItaly
-
University of MilanCompletedHepatectomy | Cirrhosis | Hepatecellular CarcinomaItaly
-
Sohag UniversityEnrolling by invitation